NCT03590613View on ClinicalTrials.gov

Phase I Study of GSK2982772 in Japanese Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

September 21, 2018

Study Completion Date

September 26, 2018

Conditions
Autoimmune Diseases
Interventions
DRUG

GSK2982772

GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route

DRUG

Placebo

Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.

Trial Locations (1)

812-0025

GSK Investigational Site, Fukuoka

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03590613 - Phase I Study of GSK2982772 in Japanese Healthy Male Participants | Biotech Hunter | Biotech Hunter